The Catalyst

Most Recent Posts

10.13.11 | By Jay Taylor, By Jay Taylor
Yesterday, Congress - with an unusually high level of bi-partisan support - passed the Korea-U.S. Free Trade Agreement. PhRMA has supported this effort for a long time and thinks that the transparency, ethical business practices and intellectual property provisions achieved in the agreement represent a good baseline for other agreements now under consideration - such as the Trans-Pacific Partnership.
10.13.11 | By Kate Connors
Former Senator Tom Daschle penned an op-ed in today's Roll Call about how preventing type 2 diabetes can help to control health care costs.
10.12.11 | By Greg Lopes
The Campaign for Modern Medicines (@modernmeds) and Eli Lilly & Company (@LillyPad) would like to invite you to join two separate Tweetchats on Medicare Part D, the prescription drug benefit program. I'm participating and I hope you will too!
10.12.11 | By Kate Connors

Our digital wizards have created another great video, this one about the more than 900 new target="_blank">biologic medicines that are currently in development to treat more than 100 diseases. It features both researchers - including the chief medical officer of Novo Nordisk, Dr.

10.11.11 | By Kate Connors

The Wall Street Journal's Laura Landro wrote today about how patients can benefit from programs that encourage improved adherence to needed medicines.

10.10.11 | By Kate Connors

Every day at PhRMA, we work to support our member companies, whose employees are dedicated to bringing new medicines to the patients who need them.

There's an interesting opinion editorial in the latest edition of the Annals of Emergency Medicine - the medical journal of the American College of Emergency Physicians (ACEP). In the op-ed, entitled "Limiting Gifts, Harming Patients" (subscription required, though copies of individual articles may be purchased), Emory University Economist Paul Rubin, Ph.D.
10.05.11 | By Kate Connors
Today, FDA released a new report, "Driving Biomedical Innovation: Initiatives for Improving Products for Patients." The report, according to the agency, is an outline of "immediate steps that can be taken to drive biomedical innovation, while improving the health of Americans." Not surprisingly, we believe this to be a tremendously vital and valuable topic of discussion.
10.04.11 | By David Roche
This past week the Manchester Journal Inquirer ran an op-ed that I wrote about a successful partnership between Connecticut's bio pharmaceutical industry and building trades unions.
Washington, D.C. (October 4, 2011) - In December 2011, Diane Bieri will step down from her role as Executive Vice President and General Counsel of the Pharmaceutical Research and Manufacturers of America (PhRMA). Bieri took over as General Counsel in April 2007. Prior to that, she served as Deputy General Counsel from 2006 to 2007. She began her career at PhRMA as the association's Compliance Officer in June 2004.

Lisa Tharp of the Ohio State Grange has written an interesting piece printed in the Columbus (OH) Dispatch: Medicare Part D plan works just fine as it is. A key insight: "...competition has driven down costs dramatically. Work from the Medicare trustees shows that the national average monthly premium for a Part D plan this year is just $30, well under the $53 projected at the program's creation.


Ah, flu season will soon be upon us. I see my supermarket and local pharmacy signing people up for this year's flu shot. Here's a piece from one of my favorite nerd sites talking about this years' vaccine and why it is important to be vaccinated.

09.26.11 | By Jay Taylor, By Jay Taylor

Last week, my colleague Grady Forrer wrote about non-communicable diseases, which are posing new and growing threats to the developing world, including countries like India.